So far, no miRNAs with sufficient sensitivity have been implemented in clinical and diagnostic practice that could serve as noninvasive markers for the diagnosis of prostate adenocarcinoma and replace the currently used but imperfect PSA marker [1,8]. Here, KLK3 is linked to prostate adenocarcinoma.